Tron Inc.’s recent moves in the TRX market are drawing attention at a time when investors are searching for signals beyond short-term price swings. Over the pastTron Inc.’s recent moves in the TRX market are drawing attention at a time when investors are searching for signals beyond short-term price swings. Over the past

TRON Doubles Down on TRX as Rising On-Chain Activity Supports Price Recovery

2026/02/10 10:30
2 min read

Tron Inc.’s recent moves in the TRX market are drawing attention at a time when investors are searching for signals beyond short-term price swings. Over the past week, the NASDAQ-listed company has steadily increased its exposure to TRX, while on-chain data points to sustained network usage.

Concurrently, these developments have helped stabilize the token after weeks of weakness, even as broader market caution remains visible in trading volumes.

Tron Inc. Expands TRX Treasury Holdings

According to disclosures shared by Justin Sun, Tron Inc. has acquired an additional 179,408 TRX at an average price of $0.28. This purchase lifted the company’s total TRX treasury holdings to roughly 680.7 million tokens.

The acquisition follows similar buys earlier in the month, including purchases on February 7 and February 8 at comparable price levels.

The company has framed its accumulation strategy as part of a longer-term approach to building a Tron-based digital asset treasury. The designated on-chain wallet for these holdings is publicly trackable on Tronscan, allowing market participants to verify the transactions directly.

While the latest purchase is modest relative to total circulating supply, the pattern of repeated accumulation has become a key data point for traders watching corporate involvement in crypto assets.

TRX Price Reaction and Market Response

TRX prices rebounded modestly following confirmation of the latest acquisition and Justin Sun’s public endorsement of the strategy. The token was trading around $0.2785 at last check, up about 0.5% on the day.

Despite the recovery, performance over longer periods remains mixed, with TRX still down on both weekly and monthly timeframes.

Trading activity suggests a more cautious market response. Reported 24-hour trading volume fell by roughly 16% to about $532 million, indicating that while prices have stabilized, participation has not fully returned.

Analysts note that corporate accumulation often provides psychological support near purchase levels, but sustained upside typically requires broader demand.

On-Chain Activity Adds Context

Beyond treasury moves, Tron’s on-chain metrics continue to show steady usage. Transaction volumes, active addresses, and smart contract interactions remain elevated, supported by stablecoin transfers and decentralized application activity across the network.

Historically, rising on-chain engagement has coincided with more resilient TRX price behavior, even during periods of uneven market sentiment. However, on-chain strength does not operate in isolation, as regulatory developments, macroeconomic conditions, and broader crypto market trends continue to influence price action.

Cover image from ChatGPT, TRONUSD chart from Tradingview

Market Opportunity
Tron Logo
Tron Price(TRX)
$0.2761
$0.2761$0.2761
-0.57%
USD
Tron (TRX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26